In a pilot trial of 12 women with taxane-induced neuropathy, cannabis capsules (100 mg CBD/5 mg THC three times daily) did not outperform placebo and actually worsened some outcomes.
Oncologists, pain specialists, breast cancer patients considering cannabis for neuropathy
What the researchers found
All 12 participants completed the 8-week trial. Both placebo and cannabis groups improved over time on measures of pain, pain interference, sleep, and well-being. However, cannabis did not improve outcomes beyond placebo, and significantly worsened several endpoints. The study demonstrated that placebo-controlled testing of cannabis capsules is feasible and well-tolerated in this population, but found no signal of efficacy at this dose.
Why it matters
Most breast cancer patients develop taxane-induced neuropathy, and there is no effective treatment. While preclinical studies showed CBD+THC synergistically reduced TIPN, this clinical trial did not replicate that benefit. The strong placebo response highlights why controlled trials are essential for evaluating cannabis as medicine.
The numbers in context
12 women; mean age 51; 8-week treatment; 100 mg CBD/5 mg THC capsules TID; both groups improved over time; cannabis worsened several endpoints vs placebo; 100% completion rate
How the study worked
Double-blind, randomized, placebo-controlled pilot study (2019-2021). 12 women with taxane-induced peripheral neuropathy (TIPN) received oral cannabis capsules (100 mg CBD/5 mg THC, TID) or placebo for 8 weeks. Daily questionnaires on pain, sleep, and medication use; weekly neuropathy assessments.
What this study cannot tell us
Very small pilot sample (N=12). Single fixed dose tested. CBD-dominant formulation may not be optimal. 8-week duration may be insufficient. Both groups requested dose reductions, suggesting tolerability issues even at these relatively low doses.
How to read the evidence
Preliminary: well-designed pilot trial but very small sample without statistical power to detect clinically meaningful differences.
When this study was published
2025 publication with data from 2019-2021
The bigger picture
The disconnect between promising preclinical data and this negative clinical result is a cautionary tale. It also illustrates why patient testimonials and uncontrolled reports of cannabis for pain are unreliable: the placebo group improved substantially.
Questions still open
- Would different CBD:THC ratios or higher THC doses show efficacy?
- Why did the preclinical promise not translate to this clinical setting?
Read the original research
Oral Cannabis for Taxane-Induced Neuropathy: A Pilot Randomized Placebo-Controlled Study.
Cannabis and cannabinoid research, 10(5), 631-639
Citation
Haney, Margaret; Choo, Tse-Hwei; Tiersten, Amy; Levin, Frances R; Grassetti, Alex; DeSilva, Natasha; Arout, Caroline A; Martinez, Diana. (2025). Oral Cannabis for Taxane-Induced Neuropathy: A Pilot Randomized Placebo-Controlled Study.. Cannabis and cannabinoid research, 10(5), 631-639. https://doi.org/10.1089/can.2025.0028
Explore the wider topic
- CBD Oil Quality Guide: How to Avoid Snake Oil
- Anxiety After Quitting Weed: When to Consider Medication
- Cannabis for Chemotherapy Nausea: What the Evidence Actually Shows
- Cannabis for Chronic Pain: What the Research Actually Supports
- Cannabis and Epilepsy: The Epidiolex Story and What It Means
- Does CBD Actually Work for Anxiety? What the Evidence Shows
- Does CBD Help with Weed Withdrawal? What Studies Show
- CBD vs THC: The Differences That Actually Matter
- The Proven Medical Benefits of Cannabis: What Research Supports
- Quitting Weed Before Surgery
- Weed and Medications: What Changes When You Quit
- Quitting Weed During Pregnancy: What You Need to Know
- Quitting Weed While Pregnant: What You Need to Know
- Cannabis and Older Adults: Risks Seniors Should Know
- Cannabis and Breastfeeding: THC in Breast Milk